Stroke in children with sickle cell anaemia: Aetiology and treatment

Paediatric Drugs

Volumn 3, Issue 6, 2001, Pages 421-432

  Pegelow, C H ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE;

ALPHA THALASSEMIA; ANEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; BRAIN ARTERY ANEURYSM; BRAIN HEMORRHAGE; BRAIN INFARCTION; CHILD; HEMOSIDEROSIS; HUMAN; HYPERTENSION; INCIDENCE; LEUKOCYTOSIS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK FACTOR; SICKLE CELL ANEMIA; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0034956445     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103060-00003     Document Type: Review

References (104)

1. Studies on the destruction of red blood cells, VII: Molecular orientation in sickle-cell hemoglobin solutions
2. Human β-globin messenger RNA: Nucleotide sequences derived from complementary DNA
3. Gene mutation in human hemoglobin: The chemical difference between normal and sickle cell hemoglobin
4. Sickle cell anemia
5. Stroke in children and sickle cell disease: Baltimore-Washington cooperative young stroke study
6. Abnormal hemoglobin as a cause of neurologic disease
7. Neurological manifestations in sickle cell disease
8. The natural history of stroke in sickle cell disease
9. Stroke in a cohort of patients with homozygous sickle cell disease
10. The involvement of the nervous system in sickle cell anemia
11. Cerebral blood flow in sickle cell cerebrovascular disease
12. Cerebrovascular accidents in sickle cell disease: Rates and risk factors
13. Cerebrovascular disease accompanying sickle cell anemia
14. Studies in sickle cell anemia: XXI. Clinicopathological aspects of neurological manifestations
15. Large cerebral vessel disease in sickle cell anemia
16. Cerebrovascular disease in sickle cell anemia: A clinical, pathological and radiological correlation
17. Occlusion of large cerebral vessels in sickle cell anemia
18. Sickle cell anemia and central nervous system infarction: A neuropathological study
19. Intracranial vessels lack vasa vasorum
20. The pathogenesis of watershed infarcts in the brain
21. Cerebral infarction in sickle cell anemia: Mechanism based on CT and MRI
22. Brain infarction in sickle cell anemia: Magnetic resonance imaging correlates
23. Easing the suffering caused by sickle cell disease
24. Prothrombotic changes in children with sickle cell disease: Relationships to cerebrovascular disease and transfusion
25. Sickled erythrocytes accelerate clotting in vitro: An effect of abnormal membrane lipid asymmetry
26. Erythrocyte membrane vesicles and irreversibly sickled cells bind protein S
27. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and β thalassaemia
28. Parvovirus B19 infection and cerebrovascular complications in homozygous sickle cell disease
29. Causes and outcomes of the acute chest syndrome in sickle cell disease
30. Nontraumatic fat embolism syndrome in sickle cell anemia
31. Neurologic events after partial exchange transfusion for priapism in sickle cell disease
32. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?
33. Alpha thalassaemia and stroke risk in sickle cell anemia
34. Cerebrovascular accidents in children with sickle cell disease and alpha thalassaemia
35. Does alpha thalassaemia protect from early stroke in sickle cell anemia?
36. Natural history of blood pressure in sickle cell disease: Risks for stroke and death associated with relative hypertension in sickle cell anemia
37. Effects of transfusion on rheological properties of blood in sickle cell anemia
38. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease
39. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients
40. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients
41. Computerized tomography complications
42. Subarachnoid hemorrhage in sickle cell disease
43. Multiple intracranial aneurysms in sickle cell anemia. Report of two cases
44. Intracranial aneurysms in sickle cell anemia: Clinical features and pathogenesis
45. Moyamoya in children with sickle cell anemia and cerebrovascular occlusion
46. Intracranial hemorrhage in children with sickle cell disease
47. Strokes and their management in sickle cell disease
48. A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction
49. Periodic transfusions for sickle cell anemia and CNS infarction
50. Transfusion therapy for cerebrovascular abnormalities in sickle cell disease
51. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease
52. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions
53. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease
54. Recurrent cerebral ischemia during hypertransfusion therapy in sickle cell anemia
55. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents
56. Transfusion and alloimmunizafion in sickle cell disease
57. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood
58. Iron-chelating therapy and the treatment of thalassaemia
59. Reassessment of the use of desferrioxamine B in iron overload
60. Rapid removal of excessive iron with daily, high dose intravenous chelation therapy
61. Evaluation of a new method of administration of the iron chelating agent deferoxamine
62. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions
63. Deferoxamine-induced growth retardation in patients with thalassaemia major
64. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage
65. Long-term safety and effectiveness of iron chelation therapy with deferiprone for thalassaemia major
66. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassaemia major
67. Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) I. Iron chelation and metabolic studies
68. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II Clinical observations
69. Results of long term deferiprone (L1) therapy: A report by the international study group on oral iron chelators
70. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease
71. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease
72. A modified transfusion program for prevention of stroke in sickle cell disease
73. Less intensive long-term transfusion therapy for sickle cell anemia and cerebrovascular accident
74. Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia
75. A cautionary note regarding hydroxyurea in sickle cell disease
76. Hydroxyurea therapy in children severely affected with sickle cell disease
77. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
78. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group
79. Delayed intracranial hemorrhage following cerebral infarction in sickle cell anemia
80. Discontinuation of long-term transfusion therapy in patients with sickle cell disease and stroke
81. Neurologic complications after allogenic marrow transplantation for sickle cell anemia
82. Bone marrow transplantation for sickle cell disease
83. Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report
84. Availability of related donors for bone marrow transplantation in sickle cell anemia
85. Cerebrovascular disease in symptomatic and asymptomatic patients with sickle cell anemia: Screening with duplex transcranial Doppler US: Correlation with MR imaging and MR angiography
86. MR imaging of the brain: Findings in asymptomatic patients with thalassaemia intermedia and sickle cell-thalassaemia disease
87. MR imaging of the brain in patients with migraine headaches
88. Brain abnormalities in male children and adolescents with hemophilia: Detection with MR imaging
89. Varied MR appearance of autism: Fifty-three pediatric patients having the full autistic syndrome
90. Transient white matter changes on MR images in children undergoing chemotherapy for acute lymphocytic leukemia: Correlation with neuropsychologic deficiencies
91. The spectrum of brain MR abnormalities in sickle cell disease: A report from the cooperative study of sickle cell disease
92. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease
93. Multicenter prospective study of children with sickle cell disease: Radiographic and psychometric correlation
94. Neuropsychologic effects of stroke in children with sickle cell anemia
95. Cognitive screening examinations for silent cerebral infarcts in sickle cell disease
96. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography
97. Children with silent infarct and elevated transcranial Doppler ultrasonography velocity are at increased risk of subsequent infarctive events
98. Risk factors for stroke in children with sickle cell disease: A report from the CSSCD
99. A multi-center comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease
100. The use of transcranial ultrasonography to predict stroke in sickle cell disease
101. Sickle cell disease and aneurismal subarachnoid hemorrhage
102. Intracranial aneurysms and sickle cell anemia: Multiplicity and propensity for the vertebrobasilar territory
103. Subarachnoid hemorrhage in sickle cell anemia: Evaluation using parenchymal and vascular magnetic resonance imaging